 - for subjects receiving anticoagulant, the subjects must, in the investigators opinion, be clinically stable with no evidence of active bleeding while receiving anticoagulant therapy. The INR for subjects on warfarin should be in the therapeutic range. Low molecular weight heparin LMWH is allowed. 